Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.51 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31255227 | 0.91 | RXFP1 (0.58) | RXFP1TFPIVIPR2VIPR1 | |
| SCHEMBL31578281 | 0.90 | GRIN2D (0.57) | RXFP1TFPIVIPR2VIPR1GRIN2D | |
| SCHEMBL29822714 | 0.90 | RXFP1 (0.57) | RXFP1TFPIVIPR2VIPR1 | |
| SCHEMBL29677393 | 0.89 | RXFP1 (0.58) | RXFP1TFPIVIPR2VIPR1 | |
| SCHEMBL30712890 | 0.89 | VIPR2 (0.58) | RXFP1VIPR2VIPR1 | |
| SCHEMBL30974358 | 0.88 | TFPI (0.57) | RXFP1TFPIVIPR2VIPR1 | |
| SCHEMBL29623995 | 0.88 | VIPR1 (0.61) | RXFP1TFPIVIPR2VIPR1 | |
| SCHEMBL29489379 | 0.87 | GRIN2D (0.55) | RXFP1TFPIVIPR2VIPR1GRIN2D | |
| SCHEMBL29489382 | 0.87 | GRIN2D (0.59) | RXFP1TFPIVIPR2VIPR1GRIN2D | |
| SCHEMBL29601022 | 0.87 | RXFP1 (0.50) | RXFP1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637447-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4650451-A1 | MRNA MOLECULE FOR TARGETED PROTEIN DEGRADATION, AND USE | Cosychem Biotechnology Technology (Tianjin) Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119876204-A | DNA molecule for targeted degradation of target protein and application | 南开大学 | 2025-04-25 | — | — | CN | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
| US-11525133-B2 | Chimeric proteins | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220226485-A1 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) | UNIVERSITY OF WASHINGTON | 2022-07-21 | — | — | US | disclosed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3983428-A1 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) | University of Washington (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114302895-A | Novel design of phosphorylation-induced protein switch (phosphate switch) | 华盛顿大学 | 2022-04-08 | — | — | CN | disclosed |
| EP-3319938-B1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | UNIV MARYLAND (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220090054-A1 | CHIMERIC PROTEINS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-11279925-B2 | Chimeric proteins | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | RXFP1 1667/4885TFPI 3482/4885VIPR2 1370/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | RXFP1 2774/4885TFPI 3747/4885VIPR2 1078/4885 |
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | MCL1, TP53, MYC | RXFP1 4607/4885TFPI 665/4885VIPR2 4704/4885 |
| US-12637447-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors | MCL1, BCL2L1, BCL2L2 | RXFP1 3319/4885TFPI 3141/4885VIPR2 4477/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | RXFP1 2963/4885TFPI 855/4885VIPR2 4686/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | RXFP1 2963/4885TFPI 855/4885VIPR2 4686/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | RXFP1 2966/4885TFPI 846/4885VIPR2 4680/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | RXFP1 4750/4885TFPI 2286/4885VIPR2 4124/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | RXFP1 4186/4885TFPI 1853/4885VIPR2 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.